We believe that by developing the user interface and leveraging the already tested algorithm, we would be able to meet the requirements under use case number 9 (MDT decision support).Nevertheless, further validation of the algorithm would be necessary and our main question is, if that could be done within INCAREHEART as part of the proposal?

We believe that by developing the user interface and leveraging the already tested algorithm, we would be able to meet the requirements under use case number 9 (MDT decision support). Nevertheless, further validation of the algorithm would be necessary and our main question is, if that could be done within INCAREHEART as part of the proposal?

The solutions will be pilot tested under real conditions in Phase III of the project, however it will not be a clinical trial and most possibly not useful for validating an algorithm. As we do not have any further information on your algorithms, we signpost you to Phase III in both TD1 and TD2.

Question number:

00-29

Date:

February 3, 2022

Asked via:

Last updated:

March 1, 2022

Scope document for the OMC

If you would like to better understand what is expected in INCAREHEART have a look at this detailed description of the building blocks and use cases. Please note that this is draft information with the purpose of consulting the market and that it might differ from the final versions included in the Call for Tenders.

OMC Questionnaire

The OMC questionnaire aims to obtain market feedback on the planned PCP and assess existing solutions. The collected input will inform the ongoing tender specifications development. Let us know what you think before the 31st of August 2021.

If you are searching partners for a joint tender and would like to appear on the Matchmaking section of this website, you can register by completing the OMC questionnaire. This part of the questionnaire will remain open until the closure of the Call for Tenders.

Scope document for the OMC

OMC Questionnaire

The INCAREHEART PCP

© 2021 empirica. All rights reserved. Incareheart has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 965134.